Insmed Inc INSM

Healthcare Biotechnology

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

NDAQ:INSM - Post by User

Insmed Inc

Bullboard Posts

Post by jamieb3on Dec 26, 2006 4:33pm

278 Views

Post# 11921439

down to 80 cents this AM

I keep looking at this stock. It was down as low as 80 cents and closed at 87. They lost the infringment case to TRCA and DNA, but have European approval. Hard to say what is going to happen. They made a better drug.

Bullboard Posts

Three mispriced stocks exposed to major market tailwinds